TAKEDA receives positive CHMP opinion for HYQVIA® as maintenance therapy in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for HYQVIA® as a maintenance therapy for patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Please find the press release here:
Other Articles You May Like
September 16, 2026
Shape The Future of CIDP Research
Study Title The Chronic Inflammatory Demyelinating Polyneuropathy-Health Index (CIDP-HI): Development of a Patient-Reported Outcome Measure…
August 19, 2026
Advocating Locally with the Foundation
There's a persistent idea in advocacy that the work happens in Washington, that unless you've…
August 17, 2026
The NAVIGATE-CIDP Study
The NAVIGATE-CIDP Study, sponsored by argenx and supported by PicnicHealth, is designed to better understand…